Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer

详细信息    查看全文

• 作者：Bo-lin Liu (5)
  Shu-juan Liu (6)
  Andrius Baskys (7)
  Hong Cheng (8)
  Ying Han (9)
  Chao Xie (10)
  Hui Song (6)
  Jia Li (6)
  Xiao-yan Xin (6)
  
  5. Department of Neurosurgery ; Xijing Institute of Clinical Neuroscience ; Xijing Hospital ; Fourth Military Medical University ; Xi鈥檃n ; Shaanxi Province ; People鈥檚 Republic of China
  6. Department of Obstetrics and Gynecology ; Xijing Hospital ; Fourth Military Medical University ; West Changle Road ; No.127 ; Xi鈥檃n ; 710032 ; Shaanxi Province ; People鈥檚 Republic of China
  7. Riverside Psychiatric Medical Group and School of Medicine ; University of California Riverside ; 5887 Brockton Avenue ; Ste. B ; Riverside ; CA ; 92506 ; USA
  8. Department of Pathology ; Xijing Hospital ; Fourth Military Medical University ; Xi鈥檃n ; Shaanxi Province ; People鈥檚 Republic of China
  9. Department of Prosthodontics ; School of Stomatology ; Fourth Military Medical University ; Xi鈥檃n ; Shaanxi Province ; People鈥檚 Republic of China
  10. Department of Dental Implantology ; School of Stomatology ; Fourth Military Medical University ; Xi鈥檃n ; Shaanxi Province ; People鈥檚 Republic of China
  
• 关键词：Brain metastases ; Chemoresistance ; Prognosis ; Stem cell marker
• 刊名：BMC Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：1,219 KB
• 参考文献：1. Pectasides, D, Pectasides, M, Economopoulos, T (2006) Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist 11: pp. 252-260 CrossRef
  2. Bruzzone, M, Campora, E, Chiara, S, Giudici, S, Merlini, L, Simoni, C, Mammoliti, S, Rubagotti, A, Rosso, R (1993) Cerebral metastases secondary to ovarian cancer: still an unusual event. Gynecol Oncol 49: pp. 37-40 CrossRef
  3. Geisler, JP, Geisler, HE (1995) Brain metastases in epithelial ovarian carcinoma. Gynecol Oncol 57: pp. 246-249 CrossRef
  4. Pietzner, K, Oskay-Oezcelik, G, El Khalfaoui, K, Boehmer, D, Lichtenegger, W, Sehouli, J (2009) Brain metastases from epithelial ovarian cancer: overview and optimal management. Anticancer Res 29: pp. 2793-2798
  5. Namikawa, K, Asakura, M, Minami, T, Okazaki, Y, Kadota, E, Hashimoto, S (2000) Toxicity of cisplatin to the central nervous system of male rabbits. Biol Trace Elem Res 74: pp. 223-235 CrossRef
  6. Melichar, B, Urminska, H, Kohlova, T, Nova, M, Cesak, T (2004) Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecol Oncol 94: pp. 267-276 CrossRef
  7. Sehouli, J, Pietzner, K, Harter, P, Munstedt, K, Mahner, S, Hasenburg, A, Camara, O, Wimberger, P, Boehmer, D, Buehling, KJ, Richter, R, El Khalfaoui, K, Oskay-Ozcelik, G (2010) Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol 21: pp. 2201-2205 CrossRef
  8. Anupol, N, Ghamande, S, Odunsi, K, Driscoll, D, Lele, S (2002) Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. Gynecol Oncol 85: pp. 487-492 CrossRef
  9. Cohen, ZR, Suki, D, Weinberg, JS, Marmor, E, Lang, FF, Gershenson, DM, Sawaya, R (2004) Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol 66: pp. 313-325 CrossRef
  10. Cormio, G, Rossi, C, Cazzolla, A, Resta, L, Loverro, G, Greco, P, Selvaggi, L (2003) Distant metastases in ovarian carcinoma. Int J Gynecol Cancer 13: pp. 125-129 CrossRef
  11. Kim, TJ, Song, S, Kim, CK, Kim, WY, Choi, CH, Lee, JH, Lee, JW, Bae, DS, Kim, BG (2007) Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer 17: pp. 1252-1257 CrossRef
  12. Pectasides, D, Aravantinos, G, Fountzilas, G, Kalofonos, C, Efstathiou, E, Karina, M, Pavlidis, N, Farmakis, D, Economopoulos, T, Dimopoulos, MA (2005) Brain metastases from epithelial ovarian cancer. the Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res 25: pp. 3553-3558
  13. Miraglia, S, Godfrey, W, Yin, AH, Atkins, K, Warnke, R, Holden, JT, Bray, RA, Waller, EK, Buck, DW (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: pp. 5013-5021
  14. Baba, T, Convery, PA, Matsumura, N, Whitaker, RS, Kondoh, E, Perry, T, Huang, Z, Bentley, RC, Mori, S, Fujii, S, Marks, JR, Berchuck, A, Murphy, SK (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28: pp. 209-218 CrossRef
  15. Curley, MD, Therrien, VA, Cummings, CL, Sergent, PA, Koulouris, CR, Friel, AM, Roberts, DJ, Seiden, MV, Scadden, DT, Rueda, BR, Foster, R (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27: pp. 2875-2883
  16. Zhang, S, Balch, C, Chan, MW, Lai, HC, Matei, D, Schilder, JM, Yan, PS, Huang, TH, Nephew, KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: pp. 4311-4320 CrossRef
  17. Zhang, J, Guo, X, Chang, DY, Rosen, DG, Mercado-Uribe, I, Liu, J (2012) CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 25: pp. 456-464 CrossRef
  18. Cheng, JX, Liu, BL, Zhang, X (2009) How powerful is CD133 as a cancer stem cell marker in brain tumors?. Cancer Treat Rev 35: pp. 403-408 CrossRef
  19. Ferrandina, G, Martinelli, E, Petrillo, M, Prisco, MG, Zannoni, G, Sioletic, S, Scambia, G (2009) CD133 antigen expression in ovarian cancer. BMC Cancer 9: pp. 221 CrossRef
  20. Liao, Y, Hu, X, Huang, X, He, C (2010) Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biol Pharm Bull 33: pp. 738-742 CrossRef
  21. Zeppernick, F, Ahmadi, R, Campos, B, Dictus, C, Helmke, BM, Becker, N, Lichter, P, Unterberg, A, Radlwimmer, B, Herold-Mende, CC (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: pp. 123-129 CrossRef
  22. Bristow, RE, Tomacruz, RS, Armstrong, DK, Trimble, EL, Montz, FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: pp. 1248-1259 CrossRef
  23. Elattar, A, Bryant, A, Winter-Roach, BA, Hatem, M, Naik, R (2011) Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev.
  24. Mizrak, D, Brittan, M, Alison, M (2008) CD133: molecule of the moment. J Pathol 214: pp. 3-9 CrossRef
  25. Zhang, SS, Han, ZP, Jing, YY, Tao, SF, Li, TJ, Wang, H, Wang, Y, Li, R, Yang, Y, Zhao, X, Xu, XD, Yu, ED, Rui, YC, Liu, HJ, Zhang, L, Wei, LX (2012) CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 10: pp. 85 CrossRef
  26. Hermann, PC, Huber, SL, Herrler, T, Aicher, A, Ellwart, JW, Guba, M, Bruns, CJ, Heeschen, C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: pp. 313-323 CrossRef
  27. Chen, K, Li, Z, Jiang, P, Zhang, X, Zhang, Y, Jiang, Y, He, Y, Li, X (2014) Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma. Oncol Rep 32: pp. 755-763
  28. Shmelkov, SV, Butler, JM, Hooper, AT, Hormigo, A, Kushner, J, Milde, T, St Clair, R, Baljevic, M, White, I, Jin, DK, Chadburn, A, Murphy, AJ, Valenzuela, DM, Gale, NW, Thurston, G, Yancopoulos, GD, D'Angelica, M, Kemeny, N, Lyden, D, Rafii, S (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118: pp. 2111-2120
  29. Choijamts, B, Jimi, S, Kondo, T, Naganuma, Y, Matsumoto, T, Kuroki, M, Iwasaki, H, Emoto, M (2011) CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mullerian tumor). Stem Cells 29: pp. 1485-1495 CrossRef
  30. Bignotti, E, Tassi, RA, Calza, S, Ravaggi, A, Bandiera, E, Rossi, E, Donzelli, C, Pasinetti, B, Pecorelli, S, Santin, AD (2007) Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol 196: pp. 245 CrossRef
  31. Alonso-Alconada, L, Muinelo-Romay, L, Madissoo, K, Diaz-Lopez, A, Krakstad, C, Trovik, J, Wik, E, Hapangama, D, Coenegrachts, L, Cano, A, Gil-Moreno, A, Chiva, L, Cueva, J, Vieito, M, Ortega, E, Mariscal, J, Colas, E, Castellvi, J, Cusido, M, Dolcet, X, Nijman, HW, Bosse, T, Green, JA, Romano, A, Reventos, J, Lopez-Lopez, R, Salvesen, HB, Amant, F, Matias-Guiu, X, Moreno-Bueno, G (2014) Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer 13: pp. 223 CrossRef
  32. Pakneshan, S, Safarpour, D, Tavassoli, F, Jabbari, B (2014) Brain metastasis from ovarian cancer: a systematic review. J Neurooncol 119: pp. 1-6 CrossRef
  33. Adler, JR, Cox, RS, Kaplan, I, Martin, DP (1992) Stereotactic radiosurgical treatment of brain metastases. J Neurosurg 76: pp. 444-449 CrossRef
  34. Alexander, E, Moriarty, TM, Davis, RB, Wen, PY, Fine, HA, Black, PM, Kooy, HM, Loeffler, JS (1995) Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87: pp. 34-40 CrossRef
  35. Lee, YK, Park, NH, Kim, JW, Song, YS, Kang, SB, Lee, HP (2008) Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer. Gynecol Oncol 108: pp. 505-509 CrossRef
  36. Brodsky, AS, Fischer, A, Miller, DH, Vang, S, MacLaughlan, S, Wu, HT, Yu, J, Steinhoff, M, Collins, C, Smith, PJ, Raphael, BJ, Brard, L (2014) Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One 9: pp. e94476 CrossRef
  37. Matsumura, N, Huang, Z, Mori, S, Baba, T, Fujii, S, Konishi, I, Iversen, ES, Berchuck, A, Murphy, SK (2011) Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res 21: pp. 74-82 CrossRef
  38. Yamamura, S, Matsumura, N, Mandai, M, Huang, Z, Oura, T, Baba, T, Hamanishi, J, Yamaguchi, K, Kang, HS, Okamoto, T, Abiko, K, Mori, S, Murphy, SK, Konishi, I (2012) The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer 130: pp. 20-28 CrossRef
  39. Baba, T, Mori, S, Matsumura, N, Kariya, M, Murphy, SK, Kondoh, E, Kusakari, T, Kuroda, H, Mandai, M, Higuchi, T, Takakura, K, Fukuda, MN, Fujii, S (2007) Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. Biochem Biophys Res Commun 360: pp. 363-369 CrossRef
  40. Hamanishi, J, Mandai, M, Abiko, K, Matsumura, N, Baba, T, Yoshioka, Y, Kosaka, K, Konishi, I (2011) The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol 141: pp. 338-347 CrossRef
  41. Abiko, K, Mandai, M, Hamanishi, J, Yoshioka, Y, Matsumura, N, Baba, T, Yamaguchi, K, Murakami, R, Yamamoto, A, Kharma, B, Kosaka, K, Konishi, I (2013) PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19: pp. 1363-1374 CrossRef
  42. Barnett, JC, Bean, SM, Whitaker, RS, Kondoh, E, Baba, T, Fujii, S, Marks, JR, Dressman, HK, Murphy, SK, Berchuck, A (2010) Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol 116: pp. 556-562 CrossRef
  43. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/829/prepub
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background To characterize prognostic and risk factors of central nervous system (CNS) metastases in patients with epithelial ovarian cancer (EOC). Methods A retrospective analysis of Xijing Hospital electronic medical records was conducted to identify patients with pathologically confirmed EOC and CNS metastases. In addition to patient demographics, tumor pathology, treatment regimens, and clinical outcomes, we compared putative cancer stem cell marker CD133 expression patterns in primary and metastatic lesions as well as in recurrent EOC with and without CNS metastases. Results Among 1366 patients with EOC, metastatic CNS lesions were present in 29 (2.1%) cases. CD133 expression in primary tumor was the only independent risk factor for CNS metastases; whilst the extent of surgical resection of primary EOC and platinum resistance were two independent factors significantly associated with time to CNS metastases. Absence of CD133 expression in primary tumors was significantly associated with high platinum sensitivity in both patient groups with and without CNS metastases. Platinum resistance and CD133 cluster formation in CNS metastases were associated with decreased survival, while multimodal therapy including stereotactic radiosurgery (SRS) for CNS metastases was associated with increased survival following the diagnosis of CNS metastases. Conclusions These data suggest that there exist a positive association between CD133 expression in primary EOC, platinum resistance and the increased risk of CNS metastases, as well as a less favorable prognosis of EOC. The absence of CD133 clusters and use of multimodal therapy including SRS could improve the outcome of metastatic lesions. Further investigation is warranted to elucidate the true nature of the association between platinum sensitivity, CD133 expression, and the risk and prognosis of CNS metastases from EOC.